亚宝药业集团股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600351 证券简称：亚宝药业 公告编号：2025-023 重要内容提示： 每股分配比例 A 股每股现金红利0.3元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/5/29 | － | 2025/5/30 | 2025/5/30 | 差异化分红送转： 否 一、 通过分配方案的股东会届次和日期 四、 分配实施办法 1. 实施办法 无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统向股权登记日上 海证券交易所收市后登记在册并在上海证券交易所各会员办理了指定交易的股东派发。已办 理指定交易的投资者可于红利发放日在其指定的证券营业部领取现金红利，未办理指定交易 的股东红利暂由中国结算上海分公司保管，待办理指定交易后再进行派发。 本次利润分配方案经公司2025 年 5 月 ...

Core Viewpoint - The company plans to repurchase shares through a centralized bidding method, with a total repurchase amount ranging from RMB 0.5 billion to RMB 1 billion, aimed at enhancing shareholder value and confidence in the company's future prospects [1][5][10]. Summary by Sections Repurchase Plan Details - The repurchase plan was first disclosed on April 26, 2025, and will be implemented within six months after approval by the shareholders' meeting [4]. - The repurchase will involve buying back between 7,194,244 and 14,388,489 shares, representing 1.03% to 2.06% of the total share capital [4][7]. - The maximum repurchase price is set at RMB 6.95 per share, which is 150% of the average trading price over the 30 trading days prior to the board's decision [2][6]. Purpose and Funding - The purpose of the repurchase is to maintain company value and protect shareholder interests, with the repurchased shares to be canceled to reduce registered capital [4][10]. - The funding for the repurchase will come from the company's own funds and self-raised funds [5][7]. Financial Impact - If the maximum repurchase amount of RMB 1 billion is utilized, it would account for approximately 2.80% of the company's total assets, 3.40% of net assets attributable to shareholders, and 6.20% of current assets as of March 31, 2025 [9][10]. - The company believes that the repurchase will not significantly impact its operations, finances, or future development [10]. Shareholder Considerations - The company has confirmed that there are no plans for share reductions by major shareholders in the next three to six months [10][11]. - The repurchase plan requires approval from the shareholders' meeting and must comply with creditor notifications to protect their interests [12]. Implementation and Adjustments - The repurchase will be executed through the Shanghai Stock Exchange trading system, and adjustments to the repurchase price may occur due to corporate actions like dividends or stock splits [6][7]. - The company has established a dedicated securities account for the repurchase [12].

Group 1 - The legal opinion letter confirms that the 2024 annual general meeting of shareholders for Yabao Pharmaceutical Group Co., Ltd. was convened and conducted in accordance with relevant laws and regulations [4][9] - The meeting was scheduled for May 16, 2025, and was announced on April 26, 2025, with all necessary documentation provided [5][6] - The meeting was attended by 4 shareholders in person, representing 63,988,100 shares, and 367 participants voted online, representing 169,190,891 shares, which accounted for 24.1701% of the total shares [7] Group 2 - The qualifications of attendees included all shareholders registered by May 9, 2025, along with directors, supervisors, senior management, and invited guests [6][7] - No new proposals were submitted by shareholders during the meeting [8] - Voting was conducted through both in-person and online methods, with results confirming that all resolutions passed met the required majority [8][9]

Group 1 - The company announced a share repurchase plan with a total fund amount between RMB 50 million and RMB 100 million, with a maximum repurchase price of RMB 6.95 per share [2] - The estimated number of shares to be repurchased ranges from 7,194,244 shares, accounting for 1.03% of the total share capital, based on the lower limit of the repurchase amount [2] - The repurchased shares will be fully canceled and will reduce the company's registered capital after the completion of the buyback [2] Group 2 - Creditors are informed that they can request the company to settle debts or provide corresponding guarantees after receiving the notice [2] - Creditors who fail to declare their claims within the specified period will not affect the validity of their claims, and the company will continue to fulfill its obligations according to the original debt documents [2] - Creditors can submit their claims through on-site, mail, or fax methods, with specific instructions provided for each submission method [2]

Group 1 - The company received the approval notice for the supplementary application of Propranolol Hydrochloride Tablets, indicating that the product has passed the consistency evaluation of generic drug quality and efficacy [1][2] - Propranolol Hydrochloride Tablets were first launched in Japan in October 1966 under the brand name Inderal, with a specification of 10mg [2] - The indications for the drug include secondary prevention of myocardial infarction mortality, hypertension treatment, control of various types of arrhythmias, and management of hyperthyroidism-related tachycardia [2] Group 2 - In 2023, the domestic sales amount of Propranolol Hydrochloride Tablets was approximately 82.18 million RMB, with public medical market sales accounting for about 57.76 million RMB and retail pharmacy sales around 24.42 million RMB [2] - As of the announcement date, six other companies in China have also passed the consistency evaluation for this drug [2] - The company has invested approximately 2.6 million RMB in the research and development of this project [2]

证券代码：600351 证券简称：亚宝药业 公告编号：2025-020 亚宝药业集团股份有限公司 关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币 0.5 亿元（含）且不超过人民币 1 亿元（含）， 具体回购资金总额以回购期满时实际回购股份使用的资金总额为准。 ● 回购股份价格：不超过人民币 6.95 元/股（含）（不高于董事会通过回购股 份决议前 30 个交易日公司股票交易均价的 150%）。 ● 相关股东是否存在减持计划：除公司控股股东外，公司不存在持股 5%以上 的股东。经问询，截至本公告日，公司控股股东、实际控制人不存在未来 3 个月、 未来 6 个月减持公司股票的计划。 ● 相关风险提示： 1、本方案尚需提交公司股东大会以特别决议审议通过，如果股东大会未能审 议通过本方案，将导致本回购计划无法实施； 2、本次回购股份用于注销，本次回购方案需征询债权人同意，存在债权人不 同意而要求提前清偿债务或要求公司提供相应担保的风险； 3 ...

证券代码：600351 证券简称：亚宝药业 公告编号：2025-022 亚宝药业集团股份有限公司 关于获得药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，亚宝药业集团股份有限公司（以下简称"公司"）控股子公司亚宝药 业太原制药有限公司（以下简称"太原制药"）收到了国家药品监督管理局（以 下简称"国家药监局"）核准签发的关于盐酸普萘洛尔片的《药品补充申请批准 通知书》（通知书编号：2025B02116），该药品通过仿制药质量和疗效一致性评价。 现将相关情况公告如下： 一、药品的基本情况 地址：太原经济技术开发区大运路 20 号 7、生产企业：亚宝药业集团股份有限公司 地址：山西省风陵渡经济开发区工业大道 1 号 8、原药品批准文号：国药准字 H14024001 9、审批结论：根据《中华人民共和国药品管理法》《国务院关于改革药品医 疗器械审评审批制度的意见》（国发〔2015〕44 号）和《关于仿制药质量和疗效 一致性评价工作有关事项的公告》（2017 年第 100 号）的规定，经审查，本品通 过 ...

证券代码：600351 证券简称：亚宝药业 公告编号：2025-021 1 亚宝药业集团股份有限公司 通知债权人公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、通知债权人的原由 亚宝药业集团股份有限公司（以下简称"公司"）于2025年5月16日召开了 2024年年度股东大会，审议通过了《关于以集中竞价交易方式回购股份方案的 议案》，具体内容详见2025年5月17日在上海证券交易所网站（www.sse.com.cn） 及《中国证券报》《上海证券报》上刊登的《亚宝药业集团股份有限公司2024 年年度股东大会决议公告》（公告编号：2025-017）。 根据本次回购方案，公司将以集中竞价交易方式回购公司股份，本次回购 资金总额不低于人民币0.5亿元（含）且不超过人民币1亿元（含），本次回购 股份价格为不超过人民币6.95元/股，按照本次回购金额下限人民币0.5亿元 （含）,回购价格上限6.95元/股进行测算，回购数量为7,194,244股，占目前公 司总股本的1.03%；按照本次回购金额上限人民币1亿元（含）,回购价格上 ...

北京市中勤律师事务所 BEIJING ZHONGQIN LAW FIRM 中国·北京市朝阳区安苑路甲 17 号 205 室 205,No.17 Anyuan Road,Chaoyang District,Beijing 100029 ,China 电话 Tel：(86-10) 85801637, 传真 Fax：(86-10) 85801653 北京市中勤律师事务所 关于亚宝药业集团股份有限公司 2024 年度 股东大会律师见证法律意见书 本所及经办律师保证本法律意见书所认定的事实真实、准确、完 整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述 或者重大遗漏。 本所同意将本法律意见书随公司其他公告文件一并予以公告，并 对法律意见书中发表的法律意见承担相应法律责任。现出具法律意见 如下： 一、本次股东会议的召集、召开程序 经本所律师核查，公司召开本次股东大会的决定是于 2025 年 4 月 24 日召开的公司第九届董事会第八次会议上表决通过的，并将会 议通知于 2025 年 4 月 26 日在《中国证券报》《上海证券报》和上海 证券交易所网站上予以公告。2025 年 5 月 9 日又在上海证券交易所 ...

证券代码：600351 证券简称：亚宝药业 公告编号：2025-019 亚宝药业集团股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (五)公司董事、监事和董事会秘书的出席情况 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 16 日 (二)股东大会召开的地点：北京市经济技术开发区天华北街 11 号院 2 号楼亚宝 药业北京企管中心 11 层会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 371 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 169,190,891 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 24.1701 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事会召集，董事长任武贤先生主持。本次会议采 ...